Financing
Proceeds from issuance of commercial paper and other short-term borrowings
Elevance Health Proceeds from issuance of commercial paper and other short-term borrowings increased by 40.6% to $724.00M in Q1 2026 compared to the prior quarter.
Analysis
StatementCash Flow Statement
SectionFinancing
CategoryLiquidity
SignalContext dependent
VolatilityModerate
First reportedQ1 2013
Last reportedQ1 2026Apr 22, 2026
How to read this metric
Higher proceeds suggest a need for short-term liquidity, while lower proceeds suggest reduced reliance on short-term credit.
Detailed definition
This represents cash inflows from the issuance of commercial paper or other short-term borrowing instruments. It reflect...
Peer comparison
Standard for companies with active treasury and working capital management programs.
Metric ID:
financing_proceeds_from_short_term_debtHistorical Data
13 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q3 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q4 '24 | Q1 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $175.00M | $0.00 | $1.20B | $90.00M | $325.00M | -$325.00M | $0.00 | $225.00M | $1.35B | $65.00M | $0.00 | $515.00M | $724.00M |
| QoQ Change | — | -100.0% | — | -92.5% | +261.1% | -200.0% | +100.0% | — | +500.0% | -95.2% | -100.0% | — | +40.6% |
| YoY Change | — | — | — | — | — | — | -100.0% | — | +315.4% | -71.1% | -100.0% | +692.3% | — |
Range-$325.00M – $1.35B
CAGR+60.5%
Avg YoY Growth+147.3%
Median YoY Growth-71.1%
Current Streak2 quarters growth
Proceeds from issuance of commercial paper and other short-term borrowings at Other Companies
Frequently Asked Questions
- What is Elevance Health's proceeds from issuance of commercial paper and other short-term borrowings?
- Elevance Health (ELV) reported proceeds from issuance of commercial paper and other short-term borrowings of $724.00M in Q1 2026.
- What does proceeds from issuance of commercial paper and other short-term borrowings mean?
- Cash received from issuing short-term debt or commercial paper.